BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer. Our proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and important tumour biomarker in cancer. Our lead product the BARD1 Lung Cancer Test is a non-invasive blood test in development for early detection of lung cancer. We are also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.



BARD1 is developing a pipeline of
cancer diagnostic and therapeutic
products based on its proprietary
BARD1 technology.

Our lead product the BARD1
Lung Cancer Test